Holen Sie sich die Stockscreener-App
2.43
0.00%
0.00
Handel nachbörslich:
2.43
Schlusskurs vom Vortag:
$2.43
Offen:
$2.42
24-Stunden-Volumen:
61,213
Relative Volume:
0.27
Marktkapitalisierung:
$120.44M
Einnahmen:
$96.63M
Nettoeinkommen (Verlust:
$-63.32M
KGV:
-1.6644
EPS:
-1.46
Netto-Cashflow:
$-54.55M
1W Leistung:
+1.67%
1M Leistung:
+10.96%
6M Leistung:
+14.08%
1J Leistung:
-45.27%
1-Tages-Spanne:
$2.39
$2.50
1-Wochen-Bereich:
$2.26
$2.50
52-Wochen-Spanne:
$1.88
$6.31
Akoya Biosciences Inc Stock (AKYA) Company Profile
Firmenname
Akoya Biosciences Inc
Sektor
Telefon
855.896.8401
Adresse
100 CAMPUS DRIVE, MARLBOROUGH
Vergleichen Sie AKYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
2.43 | 120.44M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | Craig Hallum | Buy → Hold |
| 2024-08-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Buy |
| 2022-11-03 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-06-22 | Eingeleitet | BTIG Research | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-05-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Akoya Biosciences Inc Aktie (AKYA) Neueste Nachrichten
State Street Corp Boosts Position in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Grows By 20.7% - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Analysts - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 20.7% in December - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Sold by HighTower Advisors LLC - Defense World
Charles Schwab Investment Management Inc. Decreases Stake in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences updates director and officer indemnification agreements By Investing.com - Investing.com Canada
Akoya Biosciences updates director and officer indemnification agreements - Investing.com India
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 18.1% in November - Defense World
Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower - Simply Wall St
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Expands By 18.1% - MarketBeat
Akoya Biosciences and NeraCare Enter into an Exclusive - GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions - Marketscreener.com
Nature Methods Names Spatial Proteomics 'Method of the Year 2024'Akoya Biosciences Celebrates Industry Milestone - The Manila Times
Nature Methods Names Spatial Proteomics "Method of the Year - GlobeNewswire
Akoya's Spatial Proteomics Tech Crowned 'Method of the Year 2024' by Nature Methods - StockTitan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Akoya Biosciences' SWOT analysis: spatial proteomics firm faces headwinds - Investing.com India
Akoya Biosciences' SWOT analysis: spatial proteomics firm faces headwinds By Investing.com - Investing.com UK
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Piper Sandler Reiterates “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - Defense World
Akoya Biosciences stock target cut, rating held on recent earnings report - Investing.com Canada
Akoya Biosciences' (AKYA) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Akoya Biosciences shares target cut, maintains buy rating on Q3 results - Investing.com
Craig-Hallum Downgrades Akoya Biosciences (AKYA) - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold (NASDAQ:AKYA) - Seeking Alpha
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $3.50 by Analysts at Canaccord Genuity Group - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig Hallum - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akoya Biosciences Shares Sink After FY24 Outlook Cut - MarketWatch
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 20.8% in October - MarketBeat
Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 - Marketscreener.com
Akoya: Q3 Earnings Snapshot - Darien Times
Akoya Biosciences Reports Q3 2024 Financial Results - TipRanks
Akoya Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Akoya Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akoya Biosciences (AKYA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler®-Fusion 2.0 System and the new Phenocode™ Discovery IO60 Panel from Akoya Biosciences - PR Newswire
Akoya Biosciences Unveils a New Era in Spatial Content - GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - Yahoo Finance
Finanzdaten der Akoya Biosciences Inc-Aktie (AKYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akoya Biosciences Inc-Aktie (AKYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
| McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
2.64%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):